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Therapy--related myeloid neoplasms (t--MN) are myeloid disorders, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) developing in patients treated with radiotherapy and/or chemotherapy for cancer or autoimmune diseases. Cytotoxic therapy may induce chromosomal alteration and genetic mutations in hematopoietic progenitors leading to leukemogenesis in susceptible subjects.
t--MNs are characterized by high incidence of complex karyotypes and frequent monosomies and/or deletions of chromosomes 7 and/or 5, 1 whereas the recently identified mutations of epigenetic regulators and of the spliceosome machinery are rare, with the exception of SRSF2. (2--3) Recently, new sequencing technologies have enabled large screening of somatic mutations in myeloid malignancies, leading to the discovery of new hot spot mutations in genes candidate for leukemic transformation. Among these, SET binding protein 1 (SETBP1) has been reported as frequently mutated in chronic myelomonocytic leukaemia (CMML), atypical chronic myeloid leukaemia (aCML), secondary acute myeloid leukaemia (s--AML) and in distinct subgroups of primary myelodisplastic syndromes (MDS), such as refractory anemia with excess of blasts (RAEB1 and RAEB2). (4--10) SETBP1 germline mutations are responsible of the Schinzel--Giedion syndrome (SGS), originally identified by Albert Schinzel and Andreas Giedion in 1978. It is a congenital disease characterized by a higher prevalence of tumors, severe midface hypoplasia, congenital heart defect and skeletal anomalies. 11 The SETBP1 gene is localized on chromosome 18q21.1 and the missense mutations are predominantly located in the SKI--homologous region, mainly between codon 858 and 871. Unexpectedly, frequency of SETBP1 point mutations in the SKI--homologous domain was very low in our t--MN patient cohort (3/106; 2.83%). The detected missense changes are predicted to have a damaging effect in the protein (PolyPhen2 tool). Two patients carried a G870S (COSM1234973) mutation, whereas there was one S869R mutation. The two SETBP1 G870S mutated patients were also mutated for the SRSF2 gene at position P95 (P95H and P95R with a contextual P96 insertion), whereas the carrier of S869R resulted wild type for SRSF2. Paired T--test showed a significant association (p=0.0332) between SETBP1 (3/106 patients, 2.83%) and SRSF2 (9/106 patients, 8.49%) mutations. This tight association has been previously reported by Hou et al. and Thol et al. (8, 9) No other associations between SETBP1 mutations, spliceosome machinery (SF3B1 exons 13--16 and U2AF1) and epigenetic regulators (IDH1 R132, IDH2 R140 and R172 and DNMT3A R882) somatic mutations were found.
Looking at primary disease, each of the three mutated patients had been treated for a different type of primary tumor (Non--Hodgkin lymphoma, breast and thyroid cancers), but interestingly, all patients had developed a therapy--related myelodisplastic syndrome (one RAEB1 and two RAEB2).
None of the therapy--related AML patients resulted mutated. These results reflect the figures reported by Makishima et al. and Piazza et al. who described low incidence of SETBP1 mutations in de novo AML and high frequencies in RAEB patients. (4, 6) In our t--MN patients, SETBP1 mutations were not associated to chromosome 7 abnormalities. Infact, the carriers of a G870S mutation had a complex karyotype without chromosome 7 aberrations, whereas the patient with a S869R mutation had a deletion of chromosome 7. The low number of SETBP1--mutated t--MN cases precluded the survival analysis in this cohort.
In conclusion, testing the largest t--MN cohort reported to date (106 patients), we found a low incidence of SETBP1 mutations. We confirm the association between SETBP1 and SRSF2 mutation, whereas the previously reported association between SETBP1 mutation and chromosome 7 alterations was not present in t--MN patients, suggesting that this abnormality may not be involved in the pathogenesis of these diseases. The low frequency of SETBP1 mutation in t--MN, similar to most epigenetic and spliceosome mutations, may suggest that other major changes, such as complex and monosomal karyotypes, together with TP53 mutations, may play the major role in therapy--related leukemogenesis. 
